UK availability will depend on MHRA review and approval, and timelines haven't been confirmed
Clinical studies show that individuals who combine GLP-1 medications with a balanced diet and regular exercise experience better outcomes than with medication aloneincluding improved weight management, better blood sugar control, and enhanced overall well-being
95% CI 0.630.98) and reduced risks of sepsis and infection-related mortality compared with those using dipeptidyl peptidase-4 inhibitors (115)
Underlying mechanisms contributing to cardiovascular and renal protection are at least partially different between GLP-1RAs (mainly anti-atherogenic and vascular effects) and SGLT2is (mainly systemic and intrarenal hemodynamic changes)
Mood changes This includes reports of reduced interest in pleasurable activities, low mood, and in some cases anxiety have been reported
The most frequently reported side effects were mild to moderate nausea and diarrhea